Accolade, Inc.

Accolade — Q2 2023 Earnings Presentation

30 slides from Accolade's earnings presentation, Oct 6, 2022

  1. Slide 1: Accolade Inc. Investor Presentation

    Accolade Inc. Investor Presentation

  2. Slide 2: Forward-looking statements

    This presentation contains “forward-looking statements” –that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such ‘‘anticipate,’’ ‘‘b

  3. Slide 3: The Cost of a Poor Healthcare Experience

    The Cost of a 76% Poor Healthcare of people don’t understand their available Experience benefits or how they work 88% of workers reported extreme stress, compared to 16% before the onset of COVID $225.88B in lost workforce productivity due to poor healthcare and preventable chronic conditions cost U

  4. Slide 4: Our Mission, Our Vision

    Our Mission Our mission is to empower people through expertise, empathy, and technology to make the best decisions for their health and well-being. Our Vision Our vision is every person living their healthiest life. 4

  5. Slide 5: What We Believe

    What We Believe What we believe shapes our approach to personalized healthcare HEALTHCARE IS FOR EVERYONE WHOLE PERSON HEALTHCARE RELATIONSHIPS MATTER DELIVER VALUE

  6. Slide 6: The Personalized Healthcare Experience

    The Personalized Healthcare Experience Trusted relationships. Physical and mental health. For everyone. 6

  7. Slide 7: Delivering Value Across the Entire Healthcare Journey

    Delivering Value Across the Entire Healthcare Journey Benefits Education, Utilization and Engagement Provider Selection, Care Delivery and Support Annual Open Enrollment Schedule appointment Verify benefits Address medical Research bills and ongoing Engage in care plan options treatment costs manage

  8. Slide 8: A Truly Powerful, Personalized Healthcare Platform

    A Truly Powerful, Personalized Healthcare Platform Personal | Data Driven | Value Based Accolade Accolade Accolade Advocacy Expert MD Care Personalized, trusted Real-time expert Same-day access to guidance and education for consultations for members virtual primary and mental all benefits and clinic

  9. Slide 9: Personalized Healthcare

    Personalized Healthcare Engagement cannot be solved with any single approach ACCD ENGAGEMENT MODEL Benefit Intelligent Member Utilization Provider Outreach Inquiries Inbound Services Management Search 9

  10. Slide 10: Our Engagement and Clinical Approach Drives Results

    Our Engagement and Clinical Approach Drives Results % Assisted %Provider Engagement Total Contacts 25 100% 98% 94% 93% 90% 79% 20 80% 70% 62% 15 60% 52% 42% 40% 40% 10 29% 20% 20% 5 0% 0 0 - $2500 $2.5k - $10k $10k to $25k $25k to $50k $50k to $100k $100k+ Low-spend Families Middle-spend Families Hi

  11. Slide 11: Personalized Engagement

    Personalized Engagement True Health Engine C o m p r e h e n s i v e To o l s Tr u e H e a l t h E n g i n e ID Card, Benefits, Billing, Clinical, Social, PCP Provider Search Relationship Risks Provider Services, Pre-Cert Identify up to 90% more high risk members Proactive Outreach Proven ability to

  12. Slide 12: People Power Our Solutions

    People Power Our Solutions Top Physicians Registered Nurses Health Assistants Extended Care Team & Medical Experts § From the top 50 U.S. § Varied experience § 66% degreed § Claims and Benefits medical schools across medical professionals Specialist, Logistics § Average experience disciplines § Bene

  13. Slide 13: Achieving Better Outcomes

    Achieving Better Outcomes What we know shapes what we do Build strong Address Impact Integrate Engage whole Integrate all context/social clinical high-cost behavioral population clinical needs determinants relationships members early health § 60% of high-cost § PCP use dropped 24% § 80% of a diabeti

  14. Slide 14: Personalized Healthcare Impact

    Personalized Healthcare Impact T R U E H E A LT H T R U E H E A LT H ENGINE ACTION PLAN 4.7% lower claims costs – 60+% 93% independent validation (Aon) engagement of members follow recommended action 69% 91% 98% of members state having repeat engagement of members state Accolade Accolade positively

  15. Slide 15: Engaging the Ecosystem

    Engaging the Ecosystem Connecting members to the right program, at the right time, in the right way * 13

  16. Slide 16: Accelerating Accolade's Clinical Innovation

    Accelerating Accolade’s Clinical Innovation Lowering Healthcare Spend 2021 SEPTEMBER Introduced Personalized JUNE Healthcare 2020 Added PlushCare - MARCH Virtual Primary Care Added 2nd.MD - SEPTEMBER Expert Medical 2007 - 2019 Launched Mental Opinion Health Integrated JUNE Care Launched JANUARY Acco

  17. Slide 17: Significantly Expanded Addressable Market $216 billion

    Significantly Expanded Addressable Market $216 billion TAM 700 Customers 600+ $170B 600 Primary Care 500 400+ 400 300 200 $22B 112 Expert Medical Opinion 100 54 15 20 0 $24B 18 19 ) 20 22 21 D 20 20 20 M 20 20 Navigation & Advocacy nd FY FY FY FY FY /2 (w 21 20 FY 17

  18. Slide 18: Compelling Growth Strategy

    Compelling Growth Strategy Grow customer base Further penetrate our market of 30,000+ self- and fully insured employers Retain and expand Grow relationships especially through the sale of add-on services such as Virtual Primary Care and Expert Medical customer Opinion relationships Leverage machine

  19. Slide 19: Financials

    Financials 19

  20. Slide 20: Financial Highlights

    Financial Highlights ARR Bookings & new offerings driving substantial revenue growth 30% pro forma revenue growth FY21 to FY22; Ended FY22 with $286mm ACV; Growing DTC business PMPM recurring revenue model provides significant revenue visibility Multi-year contracts with base + performance-based PMP

  21. Slide 21: Strong Revenue Growth

    Strong Revenue Growth Predictable, highly visible, and recurring revenue Revenue and FYE ACV Quarterly Revenue $ millions $ millions $310 Revenue ACV at FYE $100 FY21 FY22 FY23 $93.8 $300 $286 $90 $ 87.6 $ 85.5 $83.5 * A GR $250 % C $80 + 3 0 $73.3 A GR $211 $70 C $200 + 33% $59.5 $59.2 $170.4 $60 $

  22. Slide 22: Annual Result Trends

    Annual Result Trends Revenue Adjusted Gross Profit and Adjusted Gross Profit Margin $310.0 M $144.2 mm $170.4 M $132.5 M $77.6 mm $94.8 M $59.1 mm $34.5 mm 44.6% 45.6% 46.5% 36.4% FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 Adjusted EBITDA (Loss)* Adjusted Operating Expenses (as % of revenue) as a % of

  23. Slide 23: Revenue and Customer Growth + Unit Economics Drive Path to Profitability

    Revenue and Customer Growth + Unit Economics Drive Path to Profitability * ~20% annual revenue growth Revenue vs Adjusted EBITDA (Loss) as a % of Revenue* ($ in millions) ~$500 $358 - $365 $310 $170 $133 $77 $95 0% - 3% (10-11)% (4-5)% (16)% (13)% (25)% (41)% (56)% FY18 FY19 FY20 FY21 FY22 FY23 FY24

  24. Slide 24: Financial Targets and Goals (Non-GAAP)

    Financial Targets and Goals (Non-GAAP) Long-Term Goals Commentary Investments in technology and offering mix projected to drive GM% Adj. Gross Margin 50-55% up P&T as Projecting to continue to increase absolute dollar investments in % of Rev. 13-17% Product & Tech at a decreasing rate Adj. As sales

  25. Slide 25: Appendix

    Accolade Appendix

  26. Slide 26: Reconciliations of Revenue to Adjusted Gross Profit & Net loss to Adjusted EBITDA

    Reconciliations of Revenue to Adjusted Gross Profit & Net loss to Adjusted EBITDA Adjusted Gross Profit is a non-GAAP financial measure that we define as revenue less cost of revenue, excluding depreciation and amortization, and excluding stock-based compensation and severance costs. We define Adjus

  27. Slide 27: Adjusted EBITDA (Loss) GAAP to Non-GAAP Reconciliation

    Adjusted EBITDA (Loss) GAAP to Non-GAAP Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2018 2019 2020 2021 2022 Net Income (Loss) $ (61,286) $ (56,496) $ (51,365) $ (50,652) $ (123,124) Adjusted for: Interest expense, net 1,799 2,374 2,925 3,724 2,905 Income tax expense (benefit

  28. Slide 28: Adjusted Gross Margin GAAP to Non-GAAP Reconciliation

    Adjusted Gross Margin GAAP to Non-GAAP Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2019 2020 2021 2022 Revenue $ 94,811 $ 132,507 $ 170,358 $ 310,021 Less: Cost of revenue, excluding depreciation and (60,568) (73,685) (93,673) (169,019) amortization Gross Profit, excluding de

  29. Slide 29: Adjusted Operating Expense Reconciliation

    Adjusted Operating Expense Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2019 2020 2021 2022 Revenue $ 94,811 $ 132,507 $ 170,358 $ 310,021 Operating Expenses 88,220 107,026 123,462 266,727 Less: Depreciation and amortization (9,391) (8,516) (8,212) (42,608) Stock-based compens

  30. Slide 30: Accolade

    Accolade PERSONALIZED HEALTHCARE

Accolade — Q2 2023 Earnings Presentation on 6ix